Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 96 of 97, showing 5 Applications out of 482 total, starting on record 476, ending on 480

# Protocol No Study Title Investigator(s) & Site(s)

476.

ECCT/16/06/01   P1115
    Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
KEMRI WALTER REED PROJECT KERICHO
 
View

477.

ECCT/14/12/01   Rivaroxaban for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE)
    XALIA LEA- Xarelto® for Long-term and  Initial Anticoagulation in Venous  Thromboembolism (VTE) in Latin America,  EMEA and Asia   
Principal Investigator(s)
1. Anne Njeri Mugera Njambi Mugera
2. Dr. Martin N Wanyoike Njoroge Wanyoike
3. Charles Muthui Kariuki Muthui Kariuki
4. FEROZ ALI Allibhoy
Site(s) in Kenya
1. Primecare Heart Clinic (Nairobi City county)
2. Dr. Silversteins Clinic (Nairobi City county)
3. Nairobi Cardiovascular Clinic (Nairobi City county)
4. Agah Khan Kisumu (Kisumu county)
 
View

478.

ECCT/13/04/02  
    XANTUS EMEA-LA. Xarelto® on prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A non-interventional study   
Principal Investigator(s)
1. Dr Charles Muthui Kariuki
Site(s) in Kenya
Nairobi Cardiovascular Clinic
 
View

479.

ECCT/14/03/02   Rivaroxaban on prevention of stroke and non-central nervous system systemic embolism in patients with non valvular atrial fibrillation
    XANTUS-EL, Xarelto on prevention of stroke and non-central nervous system systemic embolism in patients with non valvular atrial fibrillation - a non interventional study, XA 1206 (IMPACT No. 16691)       
Principal Investigator(s)
1. Warshow Majid Mbarak
Site(s) in Kenya
1. MP Shah Hospital (Nairobi City county)
 
View

480.

ECCT/22/11/04   YWF:03
    YWF:03: A PHASE III, MULTICENTER, DOUBLE BLIND, RANDOMIZED STUDY OF SII YELLOW FEVER VACCINE TO COMPARE SAFETY AND IMMUNOGENICITY WITH STAMARIL®       
Principal Investigator(s)
1. Videlis Nduba
2. Otieno Walter
Site(s) in Kenya
1. KEMRI-CRDR (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
 
View